GlassScriptPhysician profile
Lena Derani
NPI 1417211780
$15,832.00
in general payments reported to CMS, 2019-2025
52 companies · $3,475 in 2025
The $3,475 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.26 · 2020: $17.15 · 2021: $1,433 · 2022: $2,915 · 2023: $3,532 · 2024: $4,439 · 2025: $3,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,445.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,632.57 | 2022-2025 | Duopa, Qulipta, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $1,484.27 | 2022-2024 | Qelbree |
| Biogen, INC. | $1,339.39 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $1,230.28 | 2021-2025 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $1,097.76 | 2021-2025 | |
| Celgene Corporation | $1,002.45 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $833.94 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $719.88 | 2022-2025 | Apokyn |
| Lilly USA, LLC | $646.69 | 2020-2025 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $620.87 | 2021-2025 | |
| Emd Serono, INC. | $438.57 | 2023-2024 | Mavenclad |
| Argenx US, INC. | $407.02 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $334.41 | 2023-2025 | Fycompa, Firdapse |
| Livanova USA, INC. | $271.30 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $265.66 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Derani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.